138 related articles for article (PubMed ID: 7508383)
1. Antagonism of the intracellular action of botulinum neurotoxin type A with monoclonal antibodies that map to light-chain epitopes.
Cenci Di Bello I; Poulain B; Shone CC; Tauc L; Dolly JO
Eur J Biochem; 1994 Jan; 219(1-2):161-9. PubMed ID: 7508383
[TBL] [Abstract][Full Text] [Related]
2. Multiple domains of botulinum neurotoxin contribute to its inhibition of transmitter release in Aplysia neurons.
Poulain B; Wadsworth JD; Shone CC; Mochida S; Lande S; Melling J; Dolly JO; Tauc L
J Biol Chem; 1989 Dec; 264(36):21928-33. PubMed ID: 2574722
[TBL] [Abstract][Full Text] [Related]
3. High-throughput homogeneous immunoassay readily identifies monoclonal antibody to serovariant clostridial neurotoxins.
Corbett CR; Elias MD; Simpson LL; Yuan XY; Cassan RR; Ballegeer E; Kabani A; Plummer FA; Berry JD
J Immunol Methods; 2007 Dec; 328(1-2):128-38. PubMed ID: 17936779
[TBL] [Abstract][Full Text] [Related]
4. The Novel Clostridial Neurotoxin Produced by Strain IBCA10-7060 Is Immunologically Equivalent to BoNT/HA.
Fan Y; Barash JR; Conrad F; Lou J; Tam C; Cheng LW; Arnon SS; Marks JD
Toxins (Basel); 2019 Dec; 12(1):. PubMed ID: 31877649
[TBL] [Abstract][Full Text] [Related]
5. Development and Characterization of Monoclonal Antibodies to Botulinum Neurotoxin Type E.
Bever CS; Scotcher M; Cheng LW; Hnasko RM; Stanker LH
Toxins (Basel); 2019 Jul; 11(7):. PubMed ID: 31337022
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the constituent chains of botulinum neurotoxins A and B in the blockade of neurotransmitter release.
Maisey EA; Wadsworth JD; Poulain B; Shone CC; Melling J; Gibbs P; Tauc L; Dolly JO
Eur J Biochem; 1988 Nov; 177(3):683-91. PubMed ID: 3197726
[TBL] [Abstract][Full Text] [Related]
7. Botulinum neurotoxins and botulism: a novel therapeutic approach.
Thanongsaksrikul J; Chaicumpa W
Toxins (Basel); 2011 May; 3(5):469-88. PubMed ID: 22069720
[TBL] [Abstract][Full Text] [Related]
8. Production of serotype C specific and serotype C/D generic monoclonal antibodies using recombinant H(C) and H(N) fragments from Clostridium botulinum neurotoxin types C(1) and D.
Curran RM; Fringuelli E; Graham D; Elliott CT
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):1-10. PubMed ID: 19233482
[TBL] [Abstract][Full Text] [Related]
9. Specific antibodies against the Zn(2+)-binding domain of clostridial neurotoxins restore exocytosis in chromaffin cells treated with tetanus or botulinum A neurotoxin.
Bartels F; Bergel H; Bigalke H; Frevert J; Halpern J; Middlebrook J
J Biol Chem; 1994 Mar; 269(11):8122-7. PubMed ID: 8132537
[TBL] [Abstract][Full Text] [Related]
10. Comparison of extracellular and intracellular potency of botulinum neurotoxins.
Cai F; Adrion CB; Keller JE
Infect Immun; 2006 Oct; 74(10):5617-24. PubMed ID: 16988237
[TBL] [Abstract][Full Text] [Related]
11. Sequence homology between tetanus and botulinum toxins detected by an antipeptide antibody.
Halpern JL; Smith LA; Seamon KB; Groover KA; Habig WH
Infect Immun; 1989 Jan; 57(1):18-22. PubMed ID: 2909486
[TBL] [Abstract][Full Text] [Related]
12. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies.
Kalb SR; Santana WI; Geren IN; Garcia-Rodriguez C; Lou J; Smith TJ; Marks JD; Smith LA; Pirkle JL; Barr JR
BMC Biochem; 2011 Nov; 12():58. PubMed ID: 22085466
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms.
Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S
Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity.
Fan Y; Geren IN; Dong J; Lou J; Wen W; Conrad F; Smith TJ; Smith LA; Ho M; Pires-Alves M; Wilson BA; Marks JD
PLoS One; 2015; 10(8):e0135306. PubMed ID: 26275214
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B.
Fan Y; Dong J; Lou J; Wen W; Conrad F; Geren IN; Garcia-Rodriguez C; Smith TJ; Smith LA; Ho M; Pires-Alves M; Wilson BA; Marks JD
Toxins (Basel); 2015 Aug; 7(9):3405-23. PubMed ID: 26343720
[TBL] [Abstract][Full Text] [Related]
16. A three monoclonal antibody combination potently neutralizes multiple botulinum neurotoxin serotype F subtypes.
Fan Y; Garcia-Rodriguez C; Lou J; Wen W; Conrad F; Zhai W; Smith TJ; Smith LA; Marks JD
PLoS One; 2017; 12(3):e0174187. PubMed ID: 28323873
[TBL] [Abstract][Full Text] [Related]
17. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
18. Production of monoclonal antibodies specific to Clostridium botulinum type B neurotoxin.
Noah CW; Poteet SS; Ramos NC; Perez JC; Huang SY
J AOAC Int; 1995; 78(2):381-5. PubMed ID: 7756853
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a monoclonal antibody recognizing an antigenic site common to Clostridium botulinum type B, C1, D, and E toxins and tetanus toxin.
Tsuzuki K; Yokosawa N; Syuto B; Ohishi I; Fujii N; Kimura K; Oguma K
Infect Immun; 1988 Apr; 56(4):898-902. PubMed ID: 2450068
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin.
Garcia-Rodriguez C; Geren IN; Lou J; Conrad F; Forsyth C; Wen W; Chakraborti S; Zao H; Manzanarez G; Smith TJ; Brown J; Tepp WH; Liu N; Wijesuriya S; Tomic MT; Johnson EA; Smith LA; Marks JD
Protein Eng Des Sel; 2011 Mar; 24(3):321-31. PubMed ID: 21149386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
